Submit to Cancers Review for Cancers Propose a Special Issue

Journal Browser

► Journal Browser

Thermal Ablation in the Management for Colorectal Liver Metastases

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: closed (29 March 2024) | Viewed by 3412

Share This Special Issue

Special Issue Editors

Prof. Dr. Martijn Meijerink

E-Mail Website
Guest Editor

Department of Radiology, Amsterdam UMC, Amsterdam, The Netherlands
Interests: interventional oncology; pancreatic ductal adenocarcinoma; irreversible electroporation; stereotactic ablative radiotherapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Dr. Robbert S. Puijk

E-Mail Website
Guest Editor

Department of Radiology, Amsterdam UMC, Amsterdam, The Netherlands
Interests: interventional radiology; computed tomography; interventional oncology

Special Issue Information

Dear Colleagues,

Targeted minimally invasive, image-guided therapies in the management of patients with colorectal liver metastases (CRLMs) play an increasingly important role in clinical oncology and health care in general. These rapidly evolving treatment modalities (e.g., microwave ablation, irreversible electroporation or stereotactic body radiation therapy) are characterized by the local delivery of (non-)thermal energy or radiation at a high dosage, directly affecting the tumor tissue in order to treat cancer more effectively. Their success is chiefly based on their minimally invasive nature, superior safety and toxicity profile, and often comparable or superior mid- and long-term oncologic outcomes, compared with conventional systemic therapy and surgical resection. The increasing role of minimally invasive, real-time, image-guided and/or navigated treatment techniques for CRLM is the primary topic of this Special Issue. We aim to procure high-quality original research and review articles that address the available kinds of (non-)thermal and radiation-related treatment options for CRLM in order to improve oncological outcomes in interventional and radiation oncology. Reports of studies highlighting the use of real-time image guiding or navigation tools or ablation confirmation techniques for volumetric assessment of the ablation zone are particularly welcome.

Prof. Dr. Martijn Meijerink
Dr. Robbert S. Puijk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

image-guided therapies
colorectal liver metastases (CRLMs)
thermal ablation
(non-)thermal and radiation-related treatment
interventional and radiation oncology

Published Papers (3 papers)

Download All Papers

Research

Jump to: Other

14 pages, 1822 KiB

Open AccessArticle

Local Treatment of Colorectal Liver Metastases in the Presence of Extrahepatic Disease: Survival Outcomes from the Amsterdam Colorectal Liver Met Registry (AmCORE)

by Hannah H. Schulz, Madelon Dijkstra, Susan van der Lei, Danielle J. W. Vos, Florentine E. F. Timmer, Robbert S. Puijk, Hester J. Scheffer, M. Petrousjka van den Tol, Birgit I. Lissenberg-Witte, Tineke E. Buffart, Kathelijn S. Versteeg, Rutger-Jan Swijnenburg and Martijn R. Meijerink

Cancers 2024, 16(6), 1098; https://doi.org/10.3390/cancers16061098 - 08 Mar 2024

Viewed by 665

Abstract

Background: The simultaneous presence of colorectal liver metastases (CRLMs) and extrahepatic metastases in patients with colorectal cancer (CRC) can be considered a relative contraindication for local treatment with curative intent. This study aims to assess the survival outcomes of patients with CRLMs and extrahepatic metastases after comprehensive local treatment of all metastatic sites. Methods: Patients with CRLMs who received local treatment of all metastatic sites were extracted from the prospective AmCORE registry database and subdivided into two groups: CRLM only vs. CRLM and extrahepatic metastasis. To address potential confounders, multivariate analysis was performed. The primary endpoint was overall survival (OS). Results: In total, 881 patients with CRLM only and 60 with CRLM and extrahepatic disease were included, and the median OS was 55.7 months vs. 42.7 months, respectively. Though OS was significantly lower in patients with concomitant extrahepatic metastases (HR 1.477; 95% CI 1.029–2.121; p = 0.033), the survival curve plateaued after 6.2 years. Extrahepatic manifestations were pulmonary (43.3%), peritoneal (16.7%) and non-regional lymph node metastases (10.0%). In patients with pulmonary and non-regional lymph node metastases, OS did not significantly differ from patients with CRLM-only disease; concomitant peritoneal metastases showed an inferior OS (HR 1.976; 95% CI 1.017–3.841, p = 0.041). Conclusions: In this comparative series, OS was inferior for patients with multi-organ metastatic CRC versus patients with CRLMs alone. Nonetheless, the long-term survival curve plateau seemed to justify local treatment in a subset of patients with multi-organ metastatic CRC, especially for patients with CRLMs and pulmonary or lymph node metastases. Full article

(This article belongs to the Special Issue Thermal Ablation in the Management for Colorectal Liver Metastases)

► Show Figures

Figure 1

15 pages, 1306 KiB

Open AccessEditor’s ChoiceArticle

Efficacy of Thermal Ablation for Small-Size (0–3 cm) versus Intermediate-Size (3–5 cm) Colorectal Liver Metastases: Results from the Amsterdam Colorectal Liver Met Registry (AmCORE)

by Madelon Dijkstra, Susan van der Lei, Robbert S. Puijk, Hannah H. Schulz, Danielle J. W. Vos, Florentine E. F. Timmer, Hester J. Scheffer, Tineke E. Buffart, M. Petrousjka van den Tol, Birgit I. Lissenberg-Witte, Rutger-Jan Swijnenburg, Kathelijn S. Versteeg and Martijn R. Meijerink

Cancers 2023, 15(17), 4346; https://doi.org/10.3390/cancers15174346 - 31 Aug 2023

Cited by 4 | Viewed by 1375

Abstract

Purpose: Thermal ablation is widely recognized as the standard of care for small-size unresectable colorectal liver metastases (CRLM). For larger CRLM safety, local control and overall efficacy are not well established and insufficiently validated. The purpose of this comparative series was to analyze outcomes for intermediate-size versus small-size CRLM. Material and methods: Patients treated with thermal ablation between December 2000 and November 2021 for small-size and intermediate-size CRLM were included. The primary endpoints were complication rate and local control (LC). Secondary endpoints included local tumor progression-free survival (LTPFS) and overall survival (OS). Results: In total, 59 patients were included in the intermediate-size (3–5 cm) group and 221 in the small-size (0–3 cm) group. Complications were not significantly different between the two groups (p = 0.546). No significant difference between the groups was found in an overall comparison of OS (HR 1.339; 95% CI 0.824–2.176; p = 0.239). LTPFS (HR 3.388; p < 0.001) and LC (HR 3.744; p = 0.004) were superior in the small-size group. Nevertheless, the 1-, 3-, and 5-year LC for intermediate-size CRLM was still 93.9%, 85.4%, and 81.5%, and technical efficacy improved over time. Conclusions: Thermal ablation for intermediate-size unresectable CRLM is safe and induces long-term LC in the vast majority. The results of the COLLISION-XL trial (unresectable colorectal liver metastases: stereotactic body radiotherapy versus microwave ablation—a phase II randomized controlled trial for CRLM 3–5 cm) are required to provide further clarification of the role of local ablative methods for intermediate-size unresectable CRLM. Full article

(This article belongs to the Special Issue Thermal Ablation in the Management for Colorectal Liver Metastases)

► Show Figures

Figure 1

Other

Jump to: Research

28 pages, 3985 KiB

Open AccessSystematic Review

Computational Modeling of Thermal Ablation Zones in the Liver: A Systematic Review

by Gonnie C. M. van Erp, Pim Hendriks, Alexander Broersen, Coosje A. M. Verhagen, Faeze Gholamiankhah, Jouke Dijkstra and Mark C. Burgmans

Cancers 2023, 15(23), 5684; https://doi.org/10.3390/cancers15235684 - 01 Dec 2023

Cited by 1 | Viewed by 822

Abstract

Purpose: This systematic review aims to identify, evaluate, and summarize the findings of the literature on existing computational models for radiofrequency and microwave thermal liver ablation planning and compare their accuracy. Methods: A systematic literature search was performed in the MEDLINE and Web of Science databases. Characteristics of the computational model and validation method of the included articles were retrieved. Results: The literature search identified 780 articles, of which 35 were included. A total of 19 articles focused on simulating radiofrequency ablation (RFA) zones, and 16 focused on microwave ablation (MWA) zones. Out of the 16 articles simulating MWA, only 2 used in vivo experiments to validate their simulations. Out of the 19 articles simulating RFA, 10 articles used in vivo validation. Dice similarity coefficients describing the overlap between in vivo experiments and simulated RFA zones varied between 0.418 and 0.728, with mean surface deviations varying between 1.1 mm and 8.67 mm. Conclusion: Computational models to simulate ablation zones of MWA and RFA show considerable heterogeneity in model type and validation methods. It is currently unknown which model is most accurate and best suitable for use in clinical practice. Full article

(This article belongs to the Special Issue Thermal Ablation in the Management for Colorectal Liver Metastases)

► Show Figures